Coated Mongolian Aneurysm Treatment Study 1

NCT04305626 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 90

Last updated 2022-04-26

No results posted yet for this study

Summary

The purpose of this study is to assess safety and effectiveness of the p64 MW HPC or p48 MW HPC Flow Modulation Device under Dual Antiplatelet Medication.

Conditions

  • Intracranial Aneurysm
  • Aneurysm
  • Vascular Diseases

Interventions

DEVICE

Endovascular treatment of intracranial aneurysms

Endovascular treatment of intracranial aneurysms with flow diversion.

Sponsors & Collaborators

  • Phenox GmbH

    lead INDUSTRY

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-06-22
Primary Completion
2023-06-22
Completion
2023-12-30

Countries

  • Mongolia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04305626 on ClinicalTrials.gov